JENBURKT Jenburkt Pharmaceuticals Limited

Regd. Office: 93, Jayprakash Road, Andheri (West), Mumbai - 400 058. Phone: 022-67 603 603 Fax: 91-22-66943127

Ref. No. JPL/CS/2272/2026 Date: 03rd February, 2026.

To
BSE Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Script Code :**524731**

Sub. : **Outcome of Board Meeting held today, i.e. 03rd February, 2026 – Standalone Unaudited Financial Results for the quarter and nine months ended on 31st December, 2025.**

Reg. : **Regulation 30(2) and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.**

Dear Sir,

1. The Standalone Unaudited Financial Statements for the quarter and nine months ended on 31st December, 2025 have been approved and adopted by the Board, on the recommendation of Audit Committee, vide its meeting held on even date. The same has been attached herewith in the format required under Regulation 33(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.

2. The Limited Audit Review Report dated 03rd February, 2026, of Auditors of the Company, on the unaudited financial results for the quarter ended on 31st December, 2025, is also attached.

The Board Meeting commenced at 2.30 p.m. and was concluded at 5:00 p.m.

Kindly take on record the above and acknowledge.

Thanking you,

Yours faithfully,
For Jenburkt Pharmaceuticals Limited,

JENBURKT PHARMACEUTICALS LTD. MUMBAI

ASHISH R. SHAH
Sr Vice President and Company Secretary

Encl.: As Stated Above.

JENBURKT

Jenburkt Pharmaceuticals Limited

Regd. Office: 93, Jayprakash Road, Andheri (West), Mumbai - 400 058. Phone: 022-67 603 603 Fax: 91-22-66943127

Statement of Standalone Unaudited Financial Results for the Quarter & Nine Months Ended on 31st December, 2025

(Rs. in Lacs other than EPS)

		Particulars	Quarter Ended			Year to Date		Year Ended
			31-12-2025	30-09-2025	31-12-2024	31-12-2025	31-12-2024	31-03-2025
			Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I		Revenue from Operations	4302.39	4555.76	3689.30	12410.83	11064.46	15169.15
II		Other Income	181.50	207.90	158.18	595.12	484.08	672.10
III		**Total income (I + II)**	**4483.90**	**4763.66**	**3847.48**	**13005.95**	**11548.54**	**15841.25**
IV		Expenses						
	(a)	Cost of Materials Consumed	247.10	219.35	224.34	679.99	622.64	851.12
	(b)	Purchase of Stock-in-trade	782.71	628.33	493.42	1948.28	1601.47	2126.08
	(c)	Changes in inventories of Finished Goods, Stock-in-trade and WIP	-150.93	-12.04	0.87	-261.99	-48.71	-11.55
	(d)	Employee benefit expenses	1471.36	1393.25	1091.58	4036.69	3410.24	4553.58
	(e)	Finance Costs	11.55	10.74	11.03	33.28	34.15	45.28
	(f)	Depreciation and Amortisation Expense	83.25	74.39	77.86	229.89	193.66	272.79
	(g)	Other expenses	1209.17	1016.44	997.05	3058.73	2525.35	3610.67
		Total Expenses (IV)	**3654.22**	**3330.46**	**2896.15**	**9724.87**	**8338.80**	**11447.97**
V		**Profit before tax (III - IV)**	**829.68**	**1433.20**	**951.33**	**3281.08**	**3209.74**	**4393.28**
VI		Tax Expense						
	(i)	Current Tax	300.00	400.00	300.00	900.00	850.00	1190.00
	(ii)	Income Tax for previous years	0.00	0.00	0.00	0.00	0.00	17.80
	(iii)	Deferred Tax	-63.46	16.86	0.58	-7.58	7.34	-20.58
VII		**Profit after tax for the period (V-VI)**	**593.14**	**1016.34**	**650.75**	**2388.66**	**2352.40**	**3206.06**
VIII		Other Comprehensive Income						
A	(i)	Items that will not be reclassified to profit or loss	66.63	-45.10	-66.16	176.72	186.03	136.06
	(ii)	Income Tax relatiing to Items that will not be reclassified to profit or loss	-7.42	16.97	8.56	-8.21	11.97	16.80
B	(i)	Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii)	Income Tax relatiing to Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
IX		**Total Comprehensive Income for the period (VII + VIII)**	**652.35**	**988.21**	**593.16**	**2557.17**	**2550.40**	**3358.92**
		Paid up Equity Share Capital (F.V. Rs.10/- each)	**441.33**	**441.33**	**441.33**	**441.33**	**441.33**	**441.33**
X		**Earnings Per Share (in Rs.) (F.V. Rs.10/-) Basic and Diluted**	**13.44**	**23.03**	**14.75**	**54.12**	**53.30**	**72.65**

Notes:

1 The above statement of standalone unaudited financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 3rd February 2026.

2 The Company has made additional provision in Employee Benefit Expense in complaince with the new Labour Codes on Wages 2019.

3 The Company is dealing exclusively in Pharmaceuticals business segment, hence segment wise reporting is not applicable.

For Jenburkt Pharmaceuticals Ltd.

JENBURKT PHARMACEUTICALS LTD. MUMBAI

(Ashish U. Bhuta)
Chairman & Managing Director
(DIN No: 00226479)

Place : Mumbai
Date : 3rd February 2026

D.R.MEHTA & ASSOCIATES

(CHARTERED ACCOUNTANTS)

H-2, EVEREST BUILDING, 9TH FLOOR, TARDEO CIRCLE, MUMBAI - 400034
TEL: 23513758 / 23520330 FAX: 66607263, 9322508373
Email ID: info@drmehta.in, vikram@drmehta.in, ashok@drmehta.in

Limited Review Report on Unaudited Quarterly Standalone Financial Results of Jenburkt Pharmaceuticals Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015

To the Board of Directors of

Jenburkt Pharmaceuticals Limited

We have reviewed the accompanying statement of unaudited standalone financial results of JENBURKT PHARMACEUTICALS LTD for the quarter ended 31st December 2025 (the statement).

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For D.R.Mehta & Associates,
Chartered Accountants
(Firm Reg. No. 106207W)



Partner
Vikram Mehta
(Membership No. 47347)
UDIN: 26047347IFTGPI8202
Place: Mumbai
Date: 3rd February, 2026